Absynth Biologics, a biotech spin-out from the University of Sheffield, has raised £850k ($1.3m) in a venture round backed by new and existing investors. University commercialisation firm Fusion IP, which operates as Sheffield’s tech transfer office, will hold a 42.84% equity stake in Absyth post-funding after putting forward £450k. The remaining £400k came from new…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
